Potential Mechanisms Driving the Development of Psoriasis after COVID-19 Vaccine

Xiangyue Lei; Xiaoning Yan

doi:10.23977/medbm.2023.010108

Potential Mechanisms Driving the Development of Psoriasis after COVID-19 Vaccine

Download as PDF

DOI: 10.23977/medbm.2023.010108 | Downloads: 23 | Views: 600

Author(s)

Xiangyue Lei ¹, Xiaoning Yan ²

Affiliation(s)

¹ Department of Traditional Chinese Medicine, First Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang, 712046, China
² Department of Dermatology, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi'an, 710000, China

Corresponding Author

Xiaoning Yan

ABSTRACT

This paper conducts a systematic review of the pathogenesis of psoriasis with the COVID-19 vaccine, using skin inflammation as a key point and delayed inflammatory response and cytokines as potential mechanisms driving psoriasis after COVID-19 vaccination. Reports from the global Centers for Disease Control (CDC) Vaccine Adverse Event Reporting System (VAERS) data reveal that psoriasis can be newly developed or exacerbated following vaccination against novel coronavirus pneumonia (COVID-19) despite global vaccination.

KEYWORDS

COVID-19 Vaccine, Psoriasis, Delayed Inflammatory Response, Cytokines, Underlying Mechanisms

CITE THIS PAPER

Xiangyue Lei, Xiaoning Yan, Potential Mechanisms Driving the Development of Psoriasis after COVID-19 Vaccine. MEDS Basic Medicine (2023) Vol. 1: 38-43. DOI: http://dx.doi.org/10.23977/medbm.2023.010108.

REFERENCES

[1] Niebel D, Novak N, Wilhelmi J, et al. Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective. Vaccines, 2021, 9(9):944.
[2] Tummolo A M, Ricciotti M A, Meloni E, et al. Impact of the Covid-19 pandemic on palliative care provision by a hospital-based unit: results from an observational study. Ig Sanita Pubbl, 2022, 80(3):124-135.
[3] Bellinato F, Maurelli M, Gisondi P, et al. Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines. Journal of Clinical Medicine, 2021, 10(22):5344.
[4] Sun Q, Fathy R, McMahon D E, et al. COVID-19 Vaccines and the Skin: The Landscape of Cutaneous Vaccine Reactions Worldwide. Dermatol Clin, 2021, 39(4):653-673.
[5] Nagrani P, Jindal R, Goyal D. Onset/flare of psoriasis following theChAdOx1 nCoV‐19 Corona virus vaccine (Oxford‐AstraZeneca/Covishield): Report of two cases. Dermatologic Therapy, 2021, 34(5).
[6] Wu P, Huang I, Wang C, et al. New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review. American Journal of Clinical Dermatology, 2022, 23(6):775-799.
[7] Huang Y, Tsai T. Exacerbation of Psoriasis Following COVID-19 Vaccination: Report from a Single Center. Frontiers in Medicine, 2021, 8.
[8] Gunes A T, Fetil E, Akarsu S, et al. Possible Triggering Effect of Influenza Vaccination on Psoriasis. Journal of Immunology Research, 2015, 2015:1-4.
[9] Takayama K, Satoh T, Hayashi M, et al. Psoriatic skin lesions induced by BCG vaccination. Acta Derm Venereol, 2008, 88(6):621-622.
[10] Macias V C, Cunha D. Psoriasis triggered by tetanus-diphtheria vaccination. Cutaneous and Ocular Toxicology, 2012, 32(2):164-165.
[11] Pattison E, Harrison B J, Griffiths C E, et al. Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Ann Rheum Dis, 2008, 67(5):672-676.
[12] Wack S, Patton T, Ferris L K. COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence. J Am Acad Dermatol, 2021, 85(5):1274-1284.
[13] Gisondi P, Geat D, Naldi L, et al. Insights into Sars-CoV-2 vaccination in patients with chronic plaque psoriasis on systemic treatments. J Eur Acad Dermatol Venereol, 2021, 35(6):e361-e362.
[14] Skroza N, Bernardini N, Tolino E, et al. Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience. Journal of Clinical Medicine, 2021, 10(15):3355.
[15] Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Annals of the Rheumatic Diseases, 2021, 80(10):1330-1338.
[16] Curtis J R, Johnson S R, Anthony D D, et al. American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. Arthritis & Rheumatology, 2021, 73(10).
[17] Chao J, Tsai T. Psoriasis flare following ChAdOx1-S/nCoV-19 vaccination in patients with psoriasis under biologic treatment. Dermatologica Sinica, 2021, 39(4):208-209.
[18] Ohsawa R, Sano H, Ikeda M, et al. Clinical and histopathological views of morbilliform rash after COVID-19 mRNA vaccination mimic those in SARS-CoV-2 virus infection-associated cutaneous manifestations. J Dermatol Sci, 2021, 103(2):124-127.
[19] Fang T, Lin Y, Chi C. Association of psoriasis with asthma: A systematic review and meta-analysis of observational studies. Dermatologica Sinica, 2020, 38(1):22.
[20] Ricardo J W, Lipner S R. Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine. JAAD Case Reports, 2021, 17:18-20.
[21] Pesqué D, Lopez Trujillo E, Marcantonio O, et al. New‐onset and exacerbations of psoriasis after mRNA COVID‐19 vaccines: two sides of the same coin? Journal of the European Academy of Dermatology and Venereology, 2022, 36(2).
[22] Lehmann M, Schorno P, Hunger R E, et al. New onset of mainly guttate psoriasis after COVID‐19 vaccination: a case report. Journal of the European Academy of Dermatology and Venereology, 2021, 35(11):e752-e755.
[23] Baden L R, El Sahly H M, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England journal of medicine, 2021, 384(5):403-416.
[24] Polack F P, Thomas S J, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med, 2020, 383(27):2603-2615.
[25] Tan S W, Tam Y C, Pang S M. Cutaneous reactions to COVID-19 vaccines: A review. JAAD International, 2022, 7:178-186.
[26] Yao Y, Jeyanathan M, Haddadi S, et al. Induction of Autonomous Memory Alveolar Macrophages Requires T Cell Help and Is Critical to Trained Immunity. Cell, 2018, 175(6):1634-1650.
[27] Zhang Y, Cao W, Xiao M, et al. Clinical analysis of seven cases of critically ill novel coronavirus pneumonia with ischemic manifestations of the extremities. Chinese Journal of Hematology, 2020(04):302-307.
[28] Artzi O, Cohen J L, Dover J S, et al. Delayed Inflammatory Reactions to Hyaluronic Acid Fillers: A Literature Review and Proposed Treatment Algorithm. Clin Cosmet Investig Dermatol, 2020, 13:371-378.
[29] Munavalli G G, Guthridge R, Knutsen-Larson S, et al. COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronicacid dermal fillers: a challenging clinical conundrum in diagnosis and treatment. . Archives of Dermatological Research, 2022, 314(1):1-15.
[30] Ni W, Yang X, Yang D, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Critical Care, 2020, 24(1).
[31] Lachmann A, Torre D, Keenan A B, et al. Massive mining of publicly available RNA-seq data from human and mouse. Nature Communications, 2018, 9(1).
[32] Shu X, Tu XJ, Chen Y, et al. Advances in the pathogenesis and targeted therapy of psoriasis. Medical Review, 2022, 28(1):23-27.
[33] Ozaras R, Berk A, Ucar D H, et al. Covid‐19 and exacerbation of psoriasis. Dermatologic Therapy, 2020, 33(4).
[34] Chang Y, Wei W. Angiotensin II in inflammation, immunity and rheumatoid arthritis. Clin Exp Immunol, 2015, 179(2): 137-145.
[35] Alijotas-Reig J, Fernández-Figueras M T, Puig L. Late-Onset Inflammatory Adverse Reactions Related to Soft Tissue Filler Injections. Clinical Reviews in Allergy & Immunology, 2013, 45(1):97-108.
[36] Hawkes J E, Chan T C, Krueger J G. Psoriasis pathogenesis and the development of novel targeted immune therapies. Journal of Allergy and Clinical Immunology, 2017, 140(3):645-653.
[37] Johnson-Huang L M, Suárez-Fariñas M, Pierson K C, et al. A Single Intradermal Injection of IFN-γ Induces an Inflammatory State in Both Non-Lesional Psoriatic and Healthy Skin. Journal of Investigative Dermatology, 2012, 132(4): 1177-1187.
[38] Song Xiuzu, Xia Jiping, Bi Zhigang. Effect of tea polyphenols and aloesin on UVB-induced synthesis and secretion of TNF-α and IL-1β in human keratinocytes. Chinese Journal of Integrative Dermatology and Venereology, 2002 (01): 7-10.
[39] Liu X, Liang YH, Zhao XQ, et al. Synthesis, evaluation of anti-inflammatory activity and molecular docking study of bitter ginseng alkaloid TNF-α inhibitors. Computers and Applied Chemistry, 2016, 33(05):521-524.
[40] Awada B, Abdullah L, Kurban M, et al. Comment on "De novo generalized pustular psoriasis following Oxford‐AstraZeneca COVID‐19 vaccine": possible role for Type I interferons. Clinical and Experimental Dermatology, 2022, 47(2):443.
[41] Sayedahmed E E, Elkashif A, Alhashimi M, et al. Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines. Vaccines (Basel), 2020, 8(4).
[42] Saadeh D, Kurban M, Abbas O. Update on the role of plasmacytoid dendritic cells in inflammatory/autoimmune skin diseases. Experimental Dermatology, 2016, 25(6):415-421.
[43] Catapano M, Vergnano M, Romano M, et al. IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis. J Invest Dermatol, 2020, 140(4):816-826.
[44] Zhang ZH, Yan SN, Huang XUEY, et al. Advances in the pathogenesis and treatment of psoriasis combined with obesity. Journal of Shanxi Medical University, 2022, 53(4):501-505.
[45] Teijaro J R, Farber D L. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol, 2021, 21(4):195-197.

Subscription

E-Mail Alert

Downloads:	427
Visits:	13101

Potential Mechanisms Driving the Development of Psoriasis after COVID-19 Vaccine

Author(s)

Affiliation(s)

Corresponding Author

ABSTRACT

KEYWORDS

CITE THIS PAPER

REFERENCES

RESOURCES

JOIN US

PUBLICATION SERVICES

CONTACT US